Gideon Akuamoah Wiafe

Gideon Akuamoah Wiafe

Auto-generated profile, based on publicly available information

Gideon Akuamoah Wiafe

Clinical Omics and Informatics Unit, Department of Medicine, Neuroscience Institute Observatory Western Cape 7925 University of Cape Town Faculty of Health Sciences

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2023 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
DADu-Bois Asante
Du-Bois Asante
GWGideon Akuamoah Wiafe
Gideon Akuamoah Wiafe
Diabetes mellitus (DM), a complex heterogeneous metabolic disorder characterized by a defect in the function of insulin, is on the rapid rise globally. Sustained hyperglycemia which is a major sign of DM is linked to the generation of reactive oxygen species which promotes adverse complications of the disorder. Traditional herbal treatment of DM is a common practice in Africa and other tropical parts of the world. Vernonia amygdalina (VA), one of the highly researched species in the Asteraceae family, has proven to possess potent antidiabetic properties. Several phytochemicals identified in multiple extracts from VA are purported to be responsible for the antidiabetic potential of the plant. In this review, we discuss the therapeutic potential of VA in diabetes and its associated complications. We appraise the current evidence and further suggest potential areas that could be effectively exploited in future VA research on diabetes.

9 November 2021 in International Journal of Developmental Neuroscience
Verified
Journal Article
Closed access
PDF file
RBRobert Peter Biney
Robert Peter Biney
FDFrancis Tanam Djankpa
Francis Tanam Djankpa
SOSilas Acheampong Osei
Silas Acheampong Osei
DEDaniel Lawer Egbenya
Daniel Lawer Egbenya
BABenjamin Aboagye
Benjamin Aboagye
DNDavid Nuertey
David Nuertey

15 November 2023 in Clinical Complementary Medicine and Pharmacology
Verified
Journal Article
Open access
DADu-Bois Asante
Du-Bois Asante
GWGideon Akuamoah Wiafe
Gideon Akuamoah Wiafe
KTKorantema Mawuena Tsegah
Korantema Mawuena Tsegah
NDNelson Kwabla Domey
Nelson Kwabla Domey

1 January 2023 in Annals of Occupational and Environmental Medicine
Verified
Journal Article
Open access
PDF file
JEJohn Ekman
John Ekman
PQPhilip Quartey
Philip Quartey
AUAbdala Mumuni Ussif
Abdala Mumuni Ussif
NRNiklas Ricklund
Niklas Ricklund
DEDaniel Lawer Egbenya
Daniel Lawer Egbenya
FDFrancis Tanam Djankpa
Francis Tanam Djankpa
Ekman J, et al. Ann Occup Environ Med. 2023 Sep;35:e39. https://doi.org/10.35371/aoem.2023.35.e39

27 May 2026 in Wellcome Open Research
Verified
Journal Article
Open access
MNMelissa Nel
Melissa Nel
JHJeannine M Heckmann
Jeannine M Heckmann
GWGideon A Wiafe
Gideon A Wiafe
MFMohammed Ahmed Farahat
Mohammed Ahmed Farahat
NPNabeelah Peerbhai
Nabeelah Peerbhai
JHJakob Hertzberg
Jakob Hertzberg
Compound heterozygous SMN1 genotypes account for approximately 5% of spinal muscular atrophy (SMA) cases but are difficult to detect using conventional short-read sequencing due to near-identical homology between SMN1 and its paralog SMN2. We describe a patient with a decade-long diagnostic odyssey in whom whole exome and short-read whole genome sequencing failed to establish a diagnosis, despite a single SMN1 copy having been detected and dismissed as carrier status. The patient presented in childhood with progressive proximal limb weakness, tongue atrophy with fasciculations and electrophysiological evidence of chronic neurogenic disease. High-fidelity long-read whole genome sequencing resolved the SMN locus unambiguously, identifying a compound heterozygous genotype comprising an SMN1 gene deletion and a likely pathogenic missense variant (c.347 T>C; p.Ile116Thr) on the remaining allele, confirming SMA type 3. This case illustrates how long-read sequencing can resolve paralogous genomic regions intractable to short-read approaches, and highlights that a single detected SMN1 copy in a patient with a compatible phenotype warrants evaluation for a second sequence-level variant.

8 July 2025 in Scientific Reports
Verified
Journal Article
Open access
KCKimberly C. Coetzer
Kimberly C. Coetzer
FZFiras Zemzem
Firas Zemzem
Eva AkurutEva Akurut
Eva Akurut
GWGideon Akuamoah Wiafe
Gideon Akuamoah Wiafe
OAOlaitan I. Awe
Olaitan I. Awe
Following a confirmed genetic diagnosis, rare disease patients and their families encounter significant challenges in accessing diagnostic information and support. Patients and non-specialists are increasingly expected to interpret and share test results; however, existing standards are primarily designed for specialists. These standards fail to address the needs of resource-limited populations where low genomic literacy hampers accurate dissemination of genetic results. This research introduces RareInsight, an open-source, interactive dashboard designed to enhance the accessibility, comprehension, and collaboration of genetic data among patients, caregivers, clinicians, and researchers. Developed using shinydashboard, RareInsight was evaluated using whole exome sequencing data from skeletal dysplasia patients. It allows users to input and view Variant Call Format files and includes a searchable ClinVar variant table with filtering options, providing access to multiple resources based on search terms. RareInsight aims to simplify the dissemination of complex genetic information beyond the clinical setting. This dashboard serves as a pilot study demonstrating the potential of patient-centered interactive dashboards for the rare disease community.